469 related articles for article (PubMed ID: 28815409)
1. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
3. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
4. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
5. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
6. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
8. Defining the pathway to insulin-like growth factor system targeting in cancer.
Rosenzweig SA; Atreya HS
Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789
[TBL] [Abstract][Full Text] [Related]
9. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
12. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
13. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
14. Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis.
Rieunier G; Wu X; Macaulay VM; Lee AV; Weyer-Czernilofsky U; Bogenrieder T
Clin Cancer Res; 2019 Jun; 25(12):3479-3485. PubMed ID: 30745299
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R as an anti-cancer target--trials and tribulations.
Chen HX; Sharon E
Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
Gombos A; Metzger-Filho O; Dal Lago L; Awada-Hussein A
Invest New Drugs; 2012 Dec; 30(6):2433-42. PubMed ID: 22415797
[TBL] [Abstract][Full Text] [Related]
18. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
20. Targeting insulin-like growth factor type 1 receptor in cancer therapy.
Atzori F; Traina TA; Ionta MT; Massidda B
Target Oncol; 2009 Dec; 4(4):255-66. PubMed ID: 19876700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
